Frontiers in Cardiovascular Medicine (Feb 2023)
Utility of atherosclerosis-associated serum antibodies against colony-stimulating factor 2 in predicting the onset of acute ischemic stroke and prognosis of colorectal cancer
- Shu-Yang Li,
- Shu-Yang Li,
- Yoichi Yoshida,
- Yoichi Yoshida,
- Masaaki Kubota,
- Masaaki Kubota,
- Bo-Shi Zhang,
- Tomoo Matsutani,
- Masaaki Ito,
- Satoshi Yajima,
- Kimihiko Yoshida,
- Seiichiro Mine,
- Seiichiro Mine,
- Seiichiro Mine,
- Toshio Machida,
- Toshio Machida,
- Toshio Machida,
- Aiko Hayashi,
- Minoru Takemoto,
- Minoru Takemoto,
- Koutaro Yokote,
- Mikiko Ohno,
- Mikiko Ohno,
- Eiichiro Nishi,
- Eiichiro Nishi,
- Kenichiro Kitamura,
- Ikuo Kamitsukasa,
- Hirotaka Takizawa,
- Mizuki Sata,
- Mizuki Sata,
- Kazumasa Yamagishi,
- Hiroyasu Iso,
- Norie Sawada,
- Shoichiro Tsugane,
- Katsuro Iwase,
- Hideaki Shimada,
- Hideaki Shimada,
- Yasuo Iwadate,
- Yasuo Iwadate,
- Takaki Hiwasa,
- Takaki Hiwasa,
- Takaki Hiwasa,
- Takaki Hiwasa
Affiliations
- Shu-Yang Li
- Department of Neurological Surgery, Graduate School of Medicine, Chiba University, Chiba, Japan
- Shu-Yang Li
- Department of Biochemistry and Genetics, Graduate School of Medicine, Chiba University, Chiba, Japan
- Yoichi Yoshida
- Department of Neurological Surgery, Graduate School of Medicine, Chiba University, Chiba, Japan
- Yoichi Yoshida
- Comprehensive Stroke Center, Chiba University Hospital, Chiba, Japan
- Masaaki Kubota
- Department of Neurological Surgery, Graduate School of Medicine, Chiba University, Chiba, Japan
- Masaaki Kubota
- Department of Biochemistry and Genetics, Graduate School of Medicine, Chiba University, Chiba, Japan
- Bo-Shi Zhang
- Department of Neurological Surgery, Graduate School of Medicine, Chiba University, Chiba, Japan
- Tomoo Matsutani
- Department of Neurological Surgery, Graduate School of Medicine, Chiba University, Chiba, Japan
- Masaaki Ito
- Department of Clinical Oncology, Toho University Graduate School of Medicine, Tokyo, Japan
- Satoshi Yajima
- Department of Gastroenterological Surgery, Toho University Graduate School of Medicine, Tokyo, Japan
- Kimihiko Yoshida
- Department of Gastroenterological Surgery, Toho University Graduate School of Medicine, Tokyo, Japan
- Seiichiro Mine
- Department of Neurological Surgery, Graduate School of Medicine, Chiba University, Chiba, Japan
- Seiichiro Mine
- Department of Neurological Surgery, Chiba Prefectural Sawara Hospital, Chiba, Japan
- Seiichiro Mine
- Department of Neurological Surgery, Chiba Cerebral and Cardiovascular Center, Chiba, Japan
- Toshio Machida
- Department of Neurological Surgery, Graduate School of Medicine, Chiba University, Chiba, Japan
- Toshio Machida
- Department of Neurological Surgery, Chiba Cerebral and Cardiovascular Center, Chiba, Japan
- Toshio Machida
- Department of Neurosurgery, Eastern Chiba Medical Center, Chiba, Japan
- Aiko Hayashi
- Department of Endocrinology, Hematology and Gerontology, Graduate School of Medicine, Chiba University, Chiba, Japan
- Minoru Takemoto
- Department of Endocrinology, Hematology and Gerontology, Graduate School of Medicine, Chiba University, Chiba, Japan
- Minoru Takemoto
- 0Department of Diabetes, Metabolism and Endocrinology, School of Medicine, International University of Health and Welfare, Chiba, Japan
- Koutaro Yokote
- Department of Endocrinology, Hematology and Gerontology, Graduate School of Medicine, Chiba University, Chiba, Japan
- Mikiko Ohno
- 1Department of Cardiovascular Medicine, Graduate School of Medicine, Kyoto University, Kyoto, Japan
- Mikiko Ohno
- 2Department of Pharmacology, Shiga University of Medical Science, Otsu, Shiga, Japan
- Eiichiro Nishi
- 1Department of Cardiovascular Medicine, Graduate School of Medicine, Kyoto University, Kyoto, Japan
- Eiichiro Nishi
- 2Department of Pharmacology, Shiga University of Medical Science, Otsu, Shiga, Japan
- Kenichiro Kitamura
- 3Kitakurihama Takuchi Clinic, Yokosuka, Kanagawa, Japan
- Ikuo Kamitsukasa
- 4Department of Neurology, Chiba Rosai Hospital, Chiba, Japan
- Hirotaka Takizawa
- 5Port Square Kashiwado Clinic, Kashiwado Memorial Foundation, Chiba, Japan
- Mizuki Sata
- 6Department of Public Health Medicine, Faculty of Medicine, and Health Services Research and Development Center, University of Tsukuba, Tsukuba, Japan
- Mizuki Sata
- 7Department of Preventive Medicine and Public Health, Keio University School of Medicine, Tokyo, Japan
- Kazumasa Yamagishi
- 6Department of Public Health Medicine, Faculty of Medicine, and Health Services Research and Development Center, University of Tsukuba, Tsukuba, Japan
- Hiroyasu Iso
- 8Public Health, Department of Social Medicine, Osaka University Graduate School of Medicine, Suita, Japan
- Norie Sawada
- 9Division of Cohort Research, National Cancer Center Institute for Cancer Control, Tokyo, Japan
- Shoichiro Tsugane
- 9Division of Cohort Research, National Cancer Center Institute for Cancer Control, Tokyo, Japan
- Katsuro Iwase
- Department of Biochemistry and Genetics, Graduate School of Medicine, Chiba University, Chiba, Japan
- Hideaki Shimada
- Department of Clinical Oncology, Toho University Graduate School of Medicine, Tokyo, Japan
- Hideaki Shimada
- Department of Gastroenterological Surgery, Toho University Graduate School of Medicine, Tokyo, Japan
- Yasuo Iwadate
- Department of Neurological Surgery, Graduate School of Medicine, Chiba University, Chiba, Japan
- Yasuo Iwadate
- Comprehensive Stroke Center, Chiba University Hospital, Chiba, Japan
- Takaki Hiwasa
- Department of Neurological Surgery, Graduate School of Medicine, Chiba University, Chiba, Japan
- Takaki Hiwasa
- Department of Biochemistry and Genetics, Graduate School of Medicine, Chiba University, Chiba, Japan
- Takaki Hiwasa
- Comprehensive Stroke Center, Chiba University Hospital, Chiba, Japan
- Takaki Hiwasa
- Department of Clinical Oncology, Toho University Graduate School of Medicine, Tokyo, Japan
- DOI
- https://doi.org/10.3389/fcvm.2023.1042272
- Journal volume & issue
-
Vol. 10
Abstract
IntroductionAutoantibodies against inflammatory cytokines may be used for the prevention of atherosclerosis. Preclinical studies consider colony-stimulating factor 2 (CSF2) as an essential cytokine with a causal relationship to atherosclerosis and cancer. We examined the serum anti-CSF2 antibody levels in patients with atherosclerosis or solid cancer.MethodsWe measured the serum anti-CSF2 antibody levels via amplified luminescent proximity homogeneous assay-linked immunosorbent assay based on the recognition of recombinant glutathione S-transferase-fused CSF2 protein or a CSF2-derived peptide as the antigen.ResultsThe serum anti-CSF2 antibody (s-CSF2-Ab) levels were significantly higher in patients with acute ischemic stroke (AIS), acute myocardial infarction (AMI), diabetes mellitus (DM), and chronic kidney disease (CKD) compared with healthy donors (HDs). In addition, the s-CSF2-Ab levels were associated with intima-media thickness and hypertension. The analyzes of samples obtained from a Japan Public Health Center-based prospective study suggested the utility of s-CSF2-Ab as a risk factor for AIS. Furthermore, the s-CSF2-Ab levels were higher in patients with esophageal, colorectal, gastric, and lung cancer than in HDs but not in those with mammary cancer. In addition, the s-CSF2-Ab levels were associated with unfavorable postoperative prognosis in colorectal cancer (CRC). In CRC, the s-CSF2-Ab levels were more closely associated with poor prognosis in patients with p53-Ab-negative CRC despite the lack of significant association of the anti-p53 antibody (p53-Ab) levels with the overall survival.ConclusionS-CSF2-Ab was useful for the diagnosis of atherosclerosis-related AIS, AMI, DM, and CKD and could discriminate poor prognosis, especially in p53-Ab-negative CRC.
Keywords
- colony-stimulating factor 2
- acute ischemic stroke
- colorectal cancer
- antibody biomarker
- atherosclerosis
